✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Of all the growth-hormone-releasing peptides discussed in modern medicine, only one is currently approved by the US Food and Drug Administration as a prescription drug. That single fact puts tesamorelin in a category of its own. Sold under the brand name Egrifta, it has been a licensed pharmaceutical since 2010 — backed by randomised clinical trials, real-world prescribing data, and a published safety profile that almost no other peptide can match.

What it is approved for, however, is narrow: the reduction of excess visceral fat in adults living with HIV-associated lipodystrophy. The story of how clinicians and researchers have explored its potential beyond that label — for non-alcoholic fatty liver disease, age-related visceral fat, cognition, and recovery — is one of the most interesting in the entire peptide field.

This guide is the deep dive most articles refuse to write. You will learn exactly what tesamorelin is, how it works, what it is and is not approved for, what the trials actually showed, the realistic safety picture, and how it stacks up against sermorelin, ipamorelin, and direct HGH.

Tesamorelin (Egrifta): Benefits, Dosage & The Honest Science

Last updated: April 7, 2026 · Reviewed by a licensed pharmacist (MedsBase Medical Team)

What Is Tesamorelin? (Definition & Background)

Tesamorelin is a synthetic 44-amino-acid peptide analogue of human growth-hormone-releasing hormone (GHRH), modified at the N-terminus with a trans-3-hexenoic acid group that protects it from rapid enzymatic degradation. It binds the GHRH receptor on the pituitary and stimulates the body’s own pulsatile growth hormone release. It is sold as the prescription drug Egrifta.

The molecule was developed by the Canadian biopharmaceutical company Theratechnologies as an improvement on the natural GHRH peptide, which is broken down in seconds by the enzyme dipeptidyl peptidase-4 (DPP-4). By modifying the N-terminus, Theratechnologies extended the active half-life enough for clinically meaningful once-daily dosing.

The US Food and Drug Administration approved tesamorelin in November 2010 for the reduction of excess visceral adipose tissue in adult patients with HIV who had developed lipodystrophy as a side effect of long-term antiretroviral therapy. It remains on the market today as Egrifta SV, a more concentrated reformulation released in 2019 that simplified daily dosing and reduced injection volume. Health Canada and several European regulators have also granted approval for the same indication, though access varies by country and reimbursement policy.

That regulatory history is what sets it apart. Most peptides discussed in modern recovery, longevity, and body-composition medicine are sold as research chemicals or compounded preparations. The tesamorelin peptide is the rare exception — a fully reviewed, fully licensed pharmaceutical with a published prescribing label, post-marketing safety data, and patient-assistance programmes. That does not make it the right choice for every situation, but it does make it the most rigorously evaluated GHRH analogue available anywhere in the world.

How Does Tesamorelin Work? (Mechanism & Science)

Tesamorelin works by impersonating natural GHRH at the pituitary gland. The result is a clean, pulsatile release of growth hormone that mimics the body’s own youthful pattern rather than overriding it.

Here is the cascade in plain language:

1. You inject the peptide subcutaneously into the abdomen, once daily.
2. It travels to the anterior pituitary and binds the GHRH receptor on cells called somatotrophs.
3. The activated receptor prompts those cells to release a pulse of stored growth hormone into the bloodstream.
4. That growth hormone reaches the liver, which produces insulin-like growth factor 1 (IGF-1).
5. IGF-1 then drives the downstream effects on visceral fat metabolism, lean tissue, and tissue repair.

The crucial design feature is what the molecule does not do. It does not flood the bloodstream with growth hormone the way an injection of synthetic HGH does. It does not bypass the body’s negative feedback system. And it does not interfere with the natural diurnal rhythm of GH release. When somatostatin — your body’s natural brake on growth hormone — is needed, it still works exactly as designed.

The trans-3-hexenoic acid modification on the N-terminus is what makes the molecule pharmacologically practical. Native GHRH is degraded by DPP-4 within minutes of release, leaving little chance for sustained receptor activation. The modification blocks DPP-4 cleavage, extending the active half-life to roughly 26 to 38 minutes — short enough to preserve pulsatility, long enough to produce a meaningful clinical effect.

One important consequence of this mechanism is that the visceral fat reduction observed in clinical trials is closely tied to the IGF-1 increase the molecule produces. Patients who do not show meaningful IGF-1 elevation typically do not show meaningful visceral fat reduction, which is why most physicians monitor IGF-1 levels at 3 and 6 months as a check on whether the protocol is actually working.

Key Uses & Applications of Tesamorelin

The applications below break cleanly into two camps: the FDA-approved indication, which has the strongest evidence, and a growing body of off-label research that is interesting but should not be confused with established medical practice.

HIV-Associated Lipodystrophy (FDA-Approved Use)

The on-label indication for tesamorelin is the reduction of excess abdominal fat in adults living with HIV who have developed lipodystrophy as a long-term consequence of antiretroviral therapy. In the pivotal phase 3 trials, daily injection produced an average 15–18% reduction in visceral adipose tissue measured by CT scan, along with improvements in waist circumference and patient-reported body image scores. This is by far the strongest evidence base behind the molecule.

Non-Alcoholic Fatty Liver Disease (Investigational)

One of the most exciting areas of off-label research has been the use of the peptide for hepatic steatosis — the accumulation of fat inside the liver itself. A 2019 trial published in The Lancet HIV showed that daily tesamorelin reduced liver fat content by approximately 32% over 12 months in patients with HIV and NAFLD. The same trial also reported reductions in markers of liver inflammation and fibrosis progression, suggesting effects beyond simple fat redistribution. Whether the same benefit translates to non-HIV NAFLD and NASH populations is now the subject of active research, and the early signals are encouraging enough that several specialist liver centres are following the data closely.

Visceral Fat in Non-HIV Adults (Off-Label)

Because the visceral fat reduction observed in HIV patients is mediated by IGF-1 elevation rather than by anything HIV-specific, some clinicians have explored similar protocols in older adults with metabolic syndrome and central obesity. The data here is preliminary, but the underlying mechanism is consistent with what is seen on-label. This use is strictly investigational and not FDA-approved.

Cognitive & Quality-of-Life Effects

Smaller studies have looked at the impact of GHRH analogue therapy on cognitive function, particularly in older adults and in HIV patients with neurocognitive symptoms. Early findings suggest possible benefits for executive function and verbal memory, though the evidence base is much thinner than the visceral fat data. These cognitive results are intriguing but should not be the primary reason anyone considers the drug, since the effect sizes reported so far are modest and not yet replicated in large independent trials.

Tesamorelin Safety Profile, Side Effects & Dosage

Because the peptide has been through full FDA review, the safety dossier is unusually rich for a peptide. The side-effect picture below draws on the original Egrifta prescribing information, post-marketing surveillance, and the published phase 3 trial data.

The two side effects worth flagging are joint pain and elevated blood glucose. Arthralgia is the most frequent reason patients discontinue the drug in real-world use, although for most users it is mild and resolves on its own. Glucose tolerance changes are usually modest but can be clinically significant in people with pre-diabetes or established type 2 diabetes, which is why fasting glucose and HbA1c are typically checked at baseline and again at the 3-month mark.

Contraindications listed in the FDA label include known hypersensitivity, disruption of the hypothalamic-pituitary-adrenal axis, active malignancy, pregnancy, and significant hypopituitarism. The label also warns against use in patients with type 1 diabetes or poorly controlled type 2 diabetes without close glucose monitoring. The molecule should not be combined with high-dose corticosteroids, which blunt the GH response.

Standard FDA-approved dosing is 2 mg administered subcutaneously into the abdomen once daily. The label specifies that the injection should be given approximately the same time each day. Treatment is generally continued for as long as the clinical benefit outweighs side effects, with periodic IGF-1 monitoring to confirm response. Off-label dosing protocols vary widely and should always be set by a qualified physician familiar with adult endocrine medicine. It is also worth noting that benefit tends to plateau if the drug is stopped, with visceral fat gradually returning to baseline within 6 to 12 months — a pattern consistent with the body’s underlying metabolic set point reasserting itself once the GHRH signal is removed.

What Does the Research Say? (Evidence & Clinical Studies)

The published evidence base behind tesamorelin is the deepest of any peptide in the GHRH class. Below are the most frequently cited findings in the modern clinical literature.

The evidence picture for the peptide breaks down into three categories:

• Proven (FDA-approved indication): visceral adipose tissue reduction in HIV-associated lipodystrophy, IGF-1 elevation, improved waist circumference and triglycerides.
• Emerging (clinical and observational): reduction in liver fat content (NAFLD), modest improvements in selected cognitive domains, possible benefits for general visceral fat in non-HIV populations.
• Anecdotal only: athletic recovery enhancement, skin and hair improvements, broad anti-ageing benefits.

It is worth emphasising that the high-quality evidence is concentrated in HIV populations because that is where the regulatory pathway pointed. The mechanistic case for similar benefit in non-HIV adults with central obesity is reasonable but should be regarded as research-grade rather than established clinical practice.

Tesamorelin vs Alternatives — How Does It Compare?

The peptide sits at a specific point on the GHRH-class spectrum: longer-acting and more potent than sermorelin, more rigorously studied than CJC-1295, and far more conservative than direct HGH. The right comparison depends on your goal.

The simplest way to think about the hierarchy is as a ladder. Sermorelin is the lightest rung — gentle, cheap, hard to misuse. CJC-1295 sits one step up. Tesamorelin is the highest GHRH-class step before you cross into direct HGH replacement: more potent, more expensive, more rigorously evaluated, but still operating through your body’s own pituitary feedback system.

For users specifically interested in visceral fat reduction or hepatic steatosis, the molecule has a more relevant evidence base than any of its alternatives. For users who simply want gentle GH support, recovery, or sleep benefits, the cheaper sermorelin guide or the ipamorelin and CJC-1295 stack are more practical first stops.

How to Use Tesamorelin — Practical Guidance

In its FDA-approved Egrifta SV form, the peptide ships as a single-dose lyophilised powder vial paired with a sterile diluent. Compounded research-grade material is sold as a multi-dose lyophilised vial that must be reconstituted with bacteriostatic water before use. Quality, sterility, and accurate dosing are non-negotiable.

1. Source from a reputable supplier. Look for a Certificate of Analysis (COA) showing HPLC purity above 98%, mass spectrometry verification, and clear batch documentation.
2. Reconstitute carefully. Add bacteriostatic water down the side of the vial — never directly onto the lyophilised powder. Swirl gently; never shake.
3. Refrigerate immediately. Once reconstituted, store at 2–8 °C and use within 14–30 days. Do not freeze.
4. Inject subcutaneously. The FDA label specifies abdominal subcutaneous injection. Use an insulin syringe (29–31 gauge) and rotate sites between injections to reduce skin reactions.
5. Time it consistently. Inject at approximately the same time each day. The peptide is not particularly tied to bedtime in the way sermorelin is, but consistency improves both compliance and pharmacokinetic stability.
6. Monitor bloodwork. Get baseline IGF-1, fasting glucose, and HbA1c. Re-test at 3 and 6 months. Adjust or discontinue based on response and side-effect tolerance.

Quality markers worth paying for include third-party lab testing, transparent batch documentation, cold-chain shipping, and a supplier that specialises in research-grade peptides rather than miscellaneous bodybuilding products. Counterfeit and underdosed material is unfortunately common in the grey market. Browse our verified tesamorelin peptide at MedsBase for pharmaceutical-grade material with full documentation.

Frequently Asked Questions

Q: What is tesamorelin used for?
A: It is FDA-approved for the reduction of excess abdominal visceral fat in adults with HIV-associated lipodystrophy. Off-label, physicians have used it to address non-alcoholic fatty liver disease, age-related visceral fat accumulation, and metabolic syndrome under close medical supervision. The molecule works by stimulating the pituitary to release more of the body’s own growth hormone, which in turn elevates IGF-1 and drives visceral fat metabolism.

Q: How quickly does tesamorelin work?
A: IGF-1 levels typically rise within the first 2 weeks of daily injections. Visible changes in waist circumference and body composition usually take 8–12 weeks to become noticeable, with the maximum effect reported around 26 weeks in the clinical trials. The peptide is not a quick fix — it is a long-cycle treatment that rewards patience and consistent daily dosing more than aggressive short-term experimentation.

Q: Is tesamorelin FDA approved?
A: Yes. It was approved by the US FDA in November 2010 under the brand name Egrifta and is currently sold as Egrifta SV by Theratechnologies. The approved indication is the reduction of excess visceral fat in adults with HIV-associated lipodystrophy. It is the only peptide in the GHRH class with current FDA approval for any indication, which is why its evidence base is far stronger than that of most peptides discussed in modern recovery and longevity medicine.

Q: How much tesamorelin should I take?
A: The FDA-approved dose is 2 mg subcutaneously once daily, injected into the abdomen at approximately the same time each day. Off-label protocols sometimes use lower doses for general visceral fat or anti-ageing purposes. Any dose should be set by a qualified physician familiar with the molecule, particularly because of the glucose-tolerance and joint-pain considerations that often need monitoring during the first few months.

Q: Can tesamorelin help with belly fat in non-HIV patients?
A: Mechanistically, the answer is yes — the visceral fat reduction observed in HIV patients is mediated by IGF-1 elevation, not by anything HIV-specific. Several smaller off-label trials and case series support its use for general visceral fat in non-HIV adults, but this remains an investigational application without FDA approval. Anyone considering it for that purpose should do so under the supervision of a physician experienced in metabolic endocrinology.

Q: What is the difference between tesamorelin and sermorelin?
A: Both are GHRH analogues, but tesamorelin is a stabilised 44-amino-acid version with a longer half-life and stronger clinical effect, while sermorelin is the shorter 29-amino-acid fragment. Tesamorelin is the only one currently FDA-approved (for HIV lipodystrophy), has more rigorous trial data behind it, and is significantly more expensive. Sermorelin is gentler, cheaper, and better suited as a general anti-ageing entry point.

Q: Does tesamorelin cause weight loss?
A: It causes visceral fat loss, which is not the same as overall weight loss. Patients in the pivotal trials saw a meaningful reduction in waist circumference and abdominal girth without dramatic changes in total body weight. The molecule selectively redistributes body composition rather than producing the kind of scale-weight drop seen with caloric restriction or GLP-1 agonists. For most users, the cosmetic and metabolic improvements show up first in central body shape.

Q: Is tesamorelin safe long-term?
A: The 52-week extension data and post-marketing surveillance suggest acceptable long-term safety in the FDA-approved HIV population, with arthralgia and mild glucose intolerance being the most common reasons for discontinuation. Long-term safety in non-HIV populations and in off-label uses is less well characterised. As with any GHRH analogue, periodic IGF-1 monitoring and metabolic bloodwork are essential for any extended cycle.

The Bottom Line — Is Tesamorelin Worth It?

Tesamorelin occupies a unique position in the peptide world. It is the only fully FDA-approved compound in the GHRH-analogue class, the only one with phase 3 data published in journals like the New England Journal of Medicine, and the only one whose visceral fat-reduction effect has been quantified across multiple controlled trials. That regulatory and evidence pedigree is genuinely meaningful, and it should weigh heavily in any conversation about which GH-supportive peptide to consider.

The trade-off is cost and specificity. The molecule is significantly more expensive than sermorelin or compounded GHRH analogues, and its strongest evidence comes from a narrow population — HIV-associated lipodystrophy. For someone who fits that profile, or whose physician is treating a clear visceral fat or hepatic steatosis problem, it is a uniquely well-validated tool. For someone simply looking for general anti-ageing benefits, the cheaper alternatives may make more practical sense.

For adults dealing with stubborn visceral fat, NAFLD, or metabolic syndrome under proper medical guidance, the peptide remains one of the highest-confidence options in modern endocrine practice. To explore where it fits in the broader landscape, see our best peptides for muscle recovery overview, or compare directly with the sermorelin deep-dive guide and the more aggressive IGF-1 LR3 guide to see how the GH-axis tools differ in mechanism and intent.

If you have done the medical groundwork and are ready to start, the verified tesamorelin peptide at MedsBase ships with full documentation and pharmaceutical-grade purity. Used wisely under proper supervision, it is the closest thing the peptide world has to a fully evaluated, fully approved metabolic intervention.

Related Guides

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.